Objective adherence monitoring in multiple sclerosis: Initial validation and association with self-report

Multiple Sclerosis

Volumn 16, Issue 1, 2010, Pages 112-120

  Bruce, Jared M ^a   Hancock, Laura M ^a   Lynch, Sharon G ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Adherence; Compliance; Disease modifying therapy; Medication Event Monitoring System; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; DRUG MONITORING; ELECTRONICS; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; QUESTIONNAIRE; SELF REPORT; TREATMENT PERSISTENCE QUESTIONNAIRE;

ADULT; DISABILITY EVALUATION; ELECTRONICS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS; NEEDLES; PATIENT COMPLIANCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73949098392     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509351897     Document Type: Article

References (23)

1. Courtney AM, Treadaway K., Remington G., Frohman E. Multiple sclerosis. Med Clin North Am 2009 ; 93: 451-476.
2. Kieseier BC, Wiendl H., Leussink VI, Stuve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 2008 ; 255 Suppl 6 ): 15-21.
3. Goodin DS Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008 ; 71: S8 - S13.
4. Bosworth H. Medication treatment adherence. In: Bosworth H, Oddone E, Weinberger M (eds) Patient treatment adherence: concepts interventions, and measurement. London: Lawrence Erlbaum Associates, 2006.
5. Van Houtven C., Weinberger M., Carey T. Implications of nonadherence for economic evaluation and health policy. In: Bosworth H, Oddone E, Weinberger M (eds) Patient treatment adherence: concepts, interventions, and measurement. London: Lawrence Erlbaum Associates, 2006.
6. Fraser C., Morgante L., Hadjimichael O., Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004 ; 36: 120-129.
7. Haas J., Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005 ; 12: 425-431.
8. Milanese C., La Mantia L., Palumbo R., et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003 ; 74: 1689-1692.
9. Mohr DC, Boudewyn AC, Likosky W., Levine E., Goodkin DE Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001 ; 23: 125-132.
10. ORourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005 ; 11: 46-50.
11. Portaccio E., Zipoli V., Siracusa G., Sorbi S., Amato MP Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008 ; 59: 131-135.
12. Rio J., Porcel J., Tellez N., et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 ; 11: 306-309.
13. Ruggieri RM, Settipani N., Viviano L., et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003 ; 24: 361-364.
14. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 ; 61: 551-554.
15. Berger BA, Hudmon KS, Liang H. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. J Am Pharm Assoc 2004 ; 44: 445-454.
16. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007 ; 13: 1146-1152.
17. Inui TS, Carter WB, Pecoraro RE Screening for non-compliance among patients with hypertension: is self-report the best available measure?. Med Care 1981 ; 19: 1061-1064.
18. Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005 ; 58: 840-846.
19. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996 ; 46: 907-911.
20. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
21. Berger BA, Liang H., Hudmon KS Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis. J Am Pharm Assoc 2005 ; 45: 466-472.
22. Klauer T., Zettl UK Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008 ; 255 (Suppl 6). 87-92.
23. Cramer JA, Scheyer RD, Mattson RH Compliance declines between clinic visits. Arch Intern Med 1990 ; 150: 1509-1510.